With an AstraZeneca cancer drug in one hand, $37M in the other, Shanghai's Alpha Bio zooms into a PhII study
One of the more prominent Chinese venture firms in biotech has put some cash behind yet another Chinese start-up looking to develop a Big Pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
